MRK.DE
MERCK Kommanditgesellschaft auf Aktien [MRK.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MRK.DE Stock Summary
Top 10 Correlated ETFs
MRK.DE
Top 10 Correlated Stocks
MRK.DE
In the News
MRK.DE Financial details
Company Rating
Strong Buy
Market Cap
65.51B
Income
2.83B
Revenue
20.99B
Book val./share
61.36
Cash/share
5.09
Dividend
2.2
Dividend %
1.53%
Employees
62.91K
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
21.62
Forward P/E
-
PEG
-14.38
P/S
2.87
P/B
2.22
P/C
28.68
P/FCF
34.75
Quick Ratio
0.86
Current Ratio
1.56
Debt / Equity
0.36
LT Debt / Equity
0.33
-
-
EPS (TTM)
6.5
EPS next Y
-
EPS next Q
-
EPS this Y
-15.03%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
16.41%
Revenue last 5Y
5.38%
Revenue Q/Q
1.01%
EPS Q/Q
-20.59%
-
-
-
-
SMA20
-5.66%
SMA50
-0.66%
SMA100
-5.66%
Inst Own
0%
Inst Trans
0.64%
ROA
6%
ROE
11%
ROC
0.09%
Gross Margin
60%
Oper. Margin
18%
Profit Margin
14%
Payout
38%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
134.3-172.4
52W High
-15.12%
52W Low
+8.96%
RSI
36
Rel Volume
1.22
Avg Volume
288.79K
Volume
353.17K
Perf Week
-2.7%
Perf Month
-8.06%
Perf Quarter
2.31%
Perf Half Y
-1.88%
-
-
-
-
Beta
0.674
-
-
Volatility
2.84%, 4.62%
Prev Close
-0.48%
Price
146
Change
0.38%
MRK.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 37.15 | 40.33 | 45.28 | 51.13 | 48.28 | |
| Net income per share | 3.04 | 4.57 | 7.03 | 7.65 | 6.5 | |
| Operating cash flow per share | 6.57 | 8 | 10.62 | 9.8 | 8.7 | |
| Free cash flow per share | 4.22 | 4.4 | 7.35 | 5.64 | -1.69 | |
| Cash per share | 1.31 | 2.62 | 3.73 | 3.78 | 5.09 | |
| Book value per share | 41.09 | 38.98 | 49.08 | 59.63 | 61.36 | |
| Tangible book value per share | -19.33 | -15.17 | -7.36 | 0.67 | 5.43 | |
| Share holders equity per share | 41.09 | 38.98 | 49.08 | 59.63 | 61.36 | |
| Interest debt per share | 31.27 | 28.58 | 25.39 | 24.46 | 22.59 | |
| Market cap | 45.56B | 60.54B | 99.22B | 79B | 62.69B | |
| Enterprise value | 58.14B | 71.47B | 108.47B | 88B | 70.65B | |
| P/E ratio | 34.52 | 30.47 | 32.48 | 23.75 | 22.2 | |
| Price to sales ratio | 2.82 | 3.45 | 5.04 | 3.55 | 2.99 | |
| POCF ratio | 15.95 | 17.41 | 21.49 | 18.55 | 16.57 | |
| PFCF ratio | 24.83 | 31.63 | 31.05 | 32.21 | -85.53 | |
| P/B Ratio | 2.55 | 3.57 | 4.65 | 3.05 | 2.35 | |
| PTB ratio | 2.55 | 3.57 | 4.65 | 3.05 | 2.35 | |
| EV to sales | 3.6 | 4.08 | 5.51 | 3.96 | 3.37 | |
| Enterprise value over EBITDA | 13.75 | 15.11 | 18.19 | 13.05 | 12.13 | |
| EV to operating cash flow | 20.36 | 20.56 | 23.5 | 20.66 | 18.67 | |
| EV to free cash flow | 31.69 | 37.34 | 33.95 | 35.87 | -96.39 | |
| Earnings yield | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | |
| Free cash flow yield | 0.04 | 0.03 | 0.03 | 0.03 | -0.01 | |
| Debt to equity | 0.73 | 0.71 | 0.5 | 0.4 | 0.36 | |
| Debt to assets | 0.3 | 0.29 | 0.24 | 0.21 | 0.19 | |
| Net debt to EBITDA | 2.97 | 2.31 | 1.55 | 1.33 | 1.37 | |
| Current ratio | 0.76 | 1.01 | 1.05 | 1.28 | 1.42 | |
| Interest coverage | 4.45 | 7.71 | 15.36 | 19.04 | 14.86 | |
| Income quality | 2.16 | 1.74 | 1.51 | 1.28 | 1.34 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0.02 | |
| Payout ratio | 0.12 | 0.08 | 0.06 | 0.07 | 0.41 | |
| Sales general and administrative to revenue | 0.07 | 0.07 | 0.06 | 0.06 | 0.07 | |
| Research and developement to revenue | 0.14 | 0.13 | 0.12 | 0.11 | 0.12 | |
| Intangibles to total assets | 0.6 | 0.56 | 0.54 | 0.53 | 0.5 | |
| Capex to operating cash flow | -0.36 | -0.45 | -0.31 | -0.42 | -1.19 | |
| Capex to revenue | -0.06 | -0.09 | -0.07 | -0.08 | -0.22 | |
| Capex to depreciation | -0.53 | -0.81 | -0.81 | -0.89 | -2.53 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 52.98 | 63.31 | 88.09 | 101.31 | 94.7 | |
| ROIC | 0.05 | 0.08 | 0.1 | 0.09 | 0.09 | |
| Return on tangible assets | 0.08 | 0.11 | 0.15 | 0.15 | 0.11 | |
| Graham Net | -45.8 | -42.35 | -37.6 | -32.73 | -32.51 | |
| Working capital | -2.84B | 49M | 550M | 2.69B | 3.69B | |
| Tangible asset value | -8.4B | -6.6B | -3.2B | 290M | 2.36B | |
| Net current asset value | -16.9B | -15.5B | -12.96B | -10.32B | -9.97B | |
| Invested capital | 0.73 | 0.71 | 0.5 | 0.4 | 0.36 | |
| Average receivables | 4.59B | 4.88B | 5.07B | 5.57B | 5.36B | |
| Average payables | 1.6B | 1.91B | 1.66B | 1.57B | 1.68B | |
| Average inventory | 3.05B | 3.32B | 3.6B | 4.27B | 4.63B | |
| Days sales outstanding | 112.85 | 99.32 | 99.47 | 94.83 | 85.84 | |
| Days payables outstanding | 124.83 | 94.41 | 76.57 | 68.27 | 69.29 | |
| Days of inventory on hand | 203.1 | 175.9 | 193.65 | 198.27 | 181.52 | |
| Receivables turnover | 3.23 | 3.68 | 3.67 | 3.85 | 4.25 | |
| Payables turnover | 2.92 | 3.87 | 4.77 | 5.35 | 5.27 | |
| Inventory turnover | 1.8 | 2.07 | 1.88 | 1.84 | 2.01 | |
| ROE | 0.07 | 0.12 | 0.14 | 0.13 | 0.11 | |
| Capex per share | -2.35 | -3.59 | -3.27 | -4.15 | -10.39 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 13.02 | 12.17 | 12.19 | 11.9 | 12.02 | |
| Net income per share | 1.51 | 1.83 | 1.62 | 1.7 | 1.35 | |
| Operating cash flow per share | 2.33 | 1.96 | 1.43 | 2.89 | 2.42 | |
| Free cash flow per share | 1.11 | 0.46 | 0.68 | 1.82 | 1.55 | |
| Cash per share | 3.78 | 3.96 | 4.43 | 5.94 | 5.09 | |
| Book value per share | 59.63 | 60.14 | 61.41 | 64.91 | 61.36 | |
| Tangible book value per share | 0.67 | 2.76 | 4.38 | 7.16 | 5.43 | |
| Share holders equity per share | 59.63 | 60.14 | 61.41 | 64.91 | 61.36 | |
| Interest debt per share | 23.95 | 24.63 | 26.07 | 25.39 | 22.05 | |
| Market cap | 79B | 74.96B | 66.3B | 69.02B | 62.69B | |
| Enterprise value | 88B | 84.02B | 75.73B | 77.61B | 70.65B | |
| P/E ratio | 30.15 | 23.54 | 23.55 | 23.35 | 26.75 | |
| Price to sales ratio | 13.96 | 14.16 | 12.51 | 13.34 | 12 | |
| POCF ratio | 77.83 | 87.87 | 106.6 | 55 | 59.54 | |
| PFCF ratio | 163.56 | 371.07 | 224.76 | 87.04 | 92.88 | |
| P/B Ratio | 3.05 | 2.87 | 2.48 | 2.45 | 2.35 | |
| PTB ratio | 3.05 | 2.87 | 2.48 | 2.45 | 2.35 | |
| EV to sales | 15.55 | 15.87 | 14.28 | 15 | 13.52 | |
| Enterprise value over EBITDA | 53.72 | 54.73 | 49.33 | 52.3 | 52.85 | |
| EV to operating cash flow | 86.7 | 98.49 | 121.75 | 61.84 | 67.1 | |
| EV to free cash flow | 182.19 | 415.92 | 256.7 | 97.87 | 104.67 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0 | 0 | 0.01 | 0.01 | |
| Debt to equity | 0.4 | 0.41 | 0.42 | 0.39 | 0.36 | |
| Debt to assets | 0.21 | 0.22 | 0.23 | 0.22 | 0.19 | |
| Net debt to EBITDA | 5.49 | 5.9 | 6.14 | 5.79 | 5.95 | |
| Current ratio | 1.28 | 1.36 | 1.47 | 1.56 | 1.42 | |
| Interest coverage | 55.56 | 15.92 | 6.5 | 11.7 | 21.28 | |
| Income quality | 1.54 | 1.07 | 0.88 | 1.7 | 1.8 | |
| Dividend Yield | 0.01 | 0 | 0 | 0 | 0.01 | |
| Payout ratio | 1.09 | 0.11 | 0.4 | 0 | 1.48 | |
| Sales general and administrative to revenue | 0.06 | 0.07 | 0.07 | 0.06 | 0.07 | |
| Research and developement to revenue | 0.12 | 0.11 | 0.11 | 0.11 | 0.13 | |
| Intangibles to total assets | 0.53 | 0.51 | 0.51 | 0.5 | 0.5 | |
| Capex to operating cash flow | -0.52 | -0.76 | -0.53 | -0.37 | -0.36 | |
| Capex to revenue | -0.09 | -0.12 | -0.06 | -0.09 | -0.07 | |
| Capex to depreciation | -0.89 | -1.43 | -0.68 | -1.06 | -0.75 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 44.96 | 49.77 | 47.3 | 49.82 | 43.14 | |
| ROIC | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Return on tangible assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Graham Net | -32.73 | -33.63 | -32.09 | -29.65 | -32.51 | |
| Working capital | 2.69B | 3.4B | 4.17B | 4.88B | 3.69B | |
| Tangible asset value | 290M | 1.2B | 1.91B | 3.11B | 2.36B | |
| Net current asset value | -10.32B | -9.46B | -8.99B | -8.05B | -9.97B | |
| Invested capital | 0.4 | 0.41 | 0.42 | 0.39 | 0.36 | |
| Average receivables | 5.29B | 5.3B | 4.84B | 4.86B | 4.9B | |
| Average payables | 2.02B | 1.96B | 2.36B | 2.32B | 2.39B | |
| Average inventory | 4.75B | 4.76B | 4.94B | 4.98B | 4.8B | |
| Days sales outstanding | 91.84 | 82.04 | 82.26 | 84.75 | 85.04 | |
| Days payables outstanding | 62.85 | 106.1 | 101.11 | 93.41 | 98.43 | |
| Days of inventory on hand | 182.52 | 223.06 | 210.21 | 206.93 | 179.34 | |
| Receivables turnover | 0.98 | 1.1 | 1.09 | 1.06 | 1.06 | |
| Payables turnover | 1.43 | 0.85 | 0.89 | 0.96 | 0.91 | |
| Inventory turnover | 0.49 | 0.4 | 0.43 | 0.43 | 0.5 | |
| ROE | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Capex per share | -1.22 | -1.5 | -0.75 | -1.06 | -0.87 |
MRK.DE Frequently Asked Questions
What is MERCK Kommanditgesellschaft auf Aktien stock symbol ?
MERCK Kommanditgesellschaft auf Aktien is a DE stock and trading under the symbol MRK.DE
What is MERCK Kommanditgesellschaft auf Aktien stock quote today ?
MERCK Kommanditgesellschaft auf Aktien stock price is $146 today.
Is MERCK Kommanditgesellschaft auf Aktien stock public?
Yes, MERCK Kommanditgesellschaft auf Aktien is a publicly traded company.
Company Profile
- Volume Average 288.79K
- Market Capitalization 65.51B
- Employee 62.91K
- CEO Ms. Belen Garijo Lopez M.D.
- Headquarters Darmstadt,DE
- IPO Date 1998-06-26
-
Website
https://www.merckgroup.com 
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
